The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.
The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the third meeting of the ...
13d
A NEW mutant strain of mpox discovered in the Democratic Republic of Congo could be better at spreading between people, ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Africanews on MSN9d
Mpox outbreak hits Kabare amid ongoing conflict in DRCMpox is rapidly spreading in Kabare, South Kivu, as healthcare systems struggle amidst ongoing conflict in eastern DRC ...
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback